Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

AIDS research and human retroviruses - 1 Feb 2012

Garrido Carolina, de Mendoza Carmen, Alvarez Elena, García Federico, Morello Judit, Garcia Silvia, Ribera Esteban, Rodríguez-Novoa Sonia, Gutierrez Felix, Soriano Vincent

Abstract excerpt

Raltegravir (RAL) resistance is associated with the selection of integrase mutations at positions 92, 143, 148, and/or 155. A substantial proportion of RAL failures, however, occurs in the absence of these changes. An examination of RAL plasma concentrations may help in interpreting this observation. All early RAL virological failures seen at 22 clinics in Spain during 2009 were identified. HIV integrase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Sequence Analysis, RNA

Share to Treatment Failure

Source

Identifiers

PMID: 21457126
DOI: 10.1089/AID.2010.0370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.PMID 21457126Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.Semantic proximity Read ↗

Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.Semantic proximity Read ↗

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.Semantic proximity Read ↗

Dolutegravir-Associated Resistance Mutations after first-line treatment failure in BrazilSemantic proximity Read ↗

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.Semantic proximity Read ↗

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.Semantic proximity Read ↗

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.Semantic proximity Read ↗

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral TherapySemantic proximity Read ↗

Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to ElvitegravirSemantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.